Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Compression modulus of improved red clay at 1600 kPa. by Quan Shen (37564)

Subjects:

Compressive strain of improved red clay at 1600 kPa. by Quan Shen (37564)

Subjects:

<i>e-lgp</i> curve of improved red clay. by Quan Shen (37564)

Subjects:

Forest plot of the second endpoint of the clinical symptom improvement. by Jin-Min Gu (17915039)

Subjects:

MXene/Bi₂O₃ Nanocomposites as Supercapacitors for Portable Electronic Devices by Nanasaheb M. Shinde (8560572)

Subjects:

Schematic diagram of the molecular mechanism by which TRIM37 improves MS by stabilizing PEX5 through monoubiquitination. by Lai Jiang (2401513)

Subjects:

Phosphorylation as an Effective Tool to Improve Stability and Reduce Toxicity of Antimicrobial Peptides by Zufang Ba (11036420)

“…Among them, W₃BipY₈-P stood out as the most promising peptide, exhibiting similar antibacterial activity as its unphosphorylated analog W₃BipY₈ but with significantly reduced hemolytic activity (19-fold decrease), cytotoxicity (3.3-fold decrease), and an extended serum half-life 6.3 times longer than W₃BipY₈. …”

Significant associations in GWAS. by Dai Nogimura (21445649)

“…<div><p>Decreased nitric oxide (NO) production from the vascular endothelium is a major factor for vascular aging. …”

Mice subjected to chronic stress and provided with HRW exhibited a significant reduction in oxidative stress levels. by Qi He (384033)

Mice subjected to chronic stress and provided with HRW exhibited a significant reduction in lipid peroxidation levels. by Qi He (384033)

Demonstration of decreased Aβ accumulation by DA-9601 treatment. by Mijung Lee (397790)

Voxel-based whole-hemisphere analysis shows regional and dose-dependent decrease of microglia. by Francesca Catto (21253435)

BT9 did not improve survival in the orthotopic xenograft model of D425 medulloblastoma. by Zahra Motahari (6814013)

Subjects: